SLS
HealthcareSELLAS Life Sciences Group, Inc.
$5.00
+$0.65 (+14.94%)
Jan 5, 2026
Price History (1Y)
Analysis
SELLAS Life Sciences Group, Inc. is a biotechnology company within the healthcare sector. With a market capitalization of $737.21 million and 15 employees, the company operates in the biotechnology industry. The financial performance of SELLAS Life Sciences Group, Inc. indicates significant losses, with a net income of -$25,942,000 over the trailing twelve months. The company's margins are also negligible, at 0.0% for gross margin, operating margin, and profit margin. Returns on equity and assets are negative, standing at -84.3% and -44.9%, respectively. The debt-to-equity ratio is 1.31, while the current ratio is 8.28. The valuation of SELLAS Life Sciences Group, Inc. reflects a forward P/E ratio of -15.79, with a price to book ratio of 13.70. The beta, which measures volatility in relation to the market, is 2.27.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Visit website →Key Statistics
- Market Cap
- $737.21M
- P/E Ratio
- N/A
- 52-Week High
- $5.18
- 52-Week Low
- $0.85
- Avg Volume
- 6.35M
- Beta
- 2.27
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 15